---
reference_id: "PMID:32413497"
title: Antiphospholipid syndrome.
authors:
- Petri M
journal: Transl Res
year: '2020'
doi: 10.1016/j.trsl.2020.04.006
content_type: abstract_only
---

# Antiphospholipid syndrome.
**Authors:** Petri M
**Journal:** Transl Res (2020)
**DOI:** [10.1016/j.trsl.2020.04.006](https://doi.org/10.1016/j.trsl.2020.04.006)

## Content

1. Transl Res. 2020 Nov;225:70-81. doi: 10.1016/j.trsl.2020.04.006. Epub 2020 May
 12.

Antiphospholipid syndrome.

Petri M(1).

Author information:
(1)Division of Rheumatology, Johns Hopkins University School of Medicine, 
Baltimore, Maryland. Electronic address: mpetri@jhmi.edu.

Antiphospholipid syndrome is one of the more common acquired causes of 
hypercoagulability. Its major presentations are thrombotic (arterial, venous, or 
microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal 
demise, and severe pre-eclampsia). Classification criteria include 3 different 
antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 
2 glycoprotein I. Management includes both preventive strategies (low-dose 
aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.

Copyright Â© 2020 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.trsl.2020.04.006
PMCID: PMC7487027
PMID: 32413497 [Indexed for MEDLINE]